Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) is a clinical-stage pharmaceutical development company that investigates safe, already approved drugs for new disease applications. Algernon is a drug re-purposing company focused on moving these drugs efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off-label prescription writing. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases such as COVID-19 and is working to develop a proprietary injectable and slow release formulation. For more information, visit the company’s website at www.algernonpharmaceuticals.com
About The LD 500
The LD 500 is the most ambitious project in LD Micro’s 14-year history of leading the micro-cap space as an independent resource. Investors will enjoy updates from hundreds of companies that represent a wide variety of industries. Featuring some of the most prominent companies in the micro-cap world, the LD 500 also incorporates interviews and keynotes with small-cap royalty.
To view InvestorBrandNetwork’s virtual coverage, which includes one-click access to market research tools on the presenting companies, visit: http://ibn.fm/TheLD500
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.